Mitral valve repair in fibroelastic deficiency
- 511 Downloads
KeywordsOperating Room Functional Status Endocarditis Thromboembolic Event Cardiac Transplantation
Fibroelastic deficiency (FED) in the mitral valve might be challenging in certain patients. Leaflets are thin and ruptured chordae are often present. The number of techniques to be applied might be numerous and compromise long-termr esults
To evaluate long-term results in the setting of mitral valve repair (MVR) for fibroelastic deficiency since our shift towards non-resective techniques from Carpentier's classical repair options
Single-institutional retrospective study with echocardiographical and clinical follow-up performed between 2005 and 2014. End-points observed were mortality and freedom from mitral insufficiency >II/IV.
158 patients were considered to have FED and had MVR in our institution from 2005 to 2014. Mean follow-up was 1468 days. Mean age was 65,8 years. Preoperative functional status (FS) was NYHA III-IV in 61 patients (38,6%).
There were 4 in-hospital deaths (4/158) none of them in the operating room (OR) 6 out of 158 left the OR with >2+ mitral insufficiency (MI).
At discharge there were 15 deaths. Actuarial survival was 89,6% (13 deaths/154)
Freedom from >2+ MI was 92,8% (129/139) with 6 patients being reoperated during follow-up (4 underwent MV replacement and 2 cardiac transplantation).
Freedom from FS >III+ was 132/139.
No endocarditis were observed during follow-up
Long-term results for FED mitral valve repair seem to be excellent being apparently the primary option for these patients. Endocarditis and thromboembolic events appear to be almost forgotten in this setting.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.